Floatz logo

69 assets in Kidney Cancer

Therapeutic assets addressing Kidney Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Tocilizumab
Kidney Cancer
TakedaP1/2CC (43)
Vorolanib
Kidney Cancer
Cancer Institute and Hospital, Chinese Academy of Medical SciencesP1/2CC (43)
18F-CAIX-LT-BCH
Kidney Cancer
Peking University Cancer Hospital & InstituteEarly P1C (39)
Atezolizumab
Kidney Cancer
Oliver JonasP1C (39)
aur106
Kidney Cancer
Aurigene Discovery Technologies LimitedP1C (39)
Brodalumab
Kidney Cancer
Brian Henick, MDP1C (39)
dk210
Kidney Cancer
DEKA BiosciencesP1C (39)
hc-7366
Kidney Cancer
M.D. Anderson Cancer CenterP1C (39)
mk-3795
Kidney Cancer
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)P1C (39)
Neovax
Kidney Cancer
Patrick Ott, MD, PhDP1C (39)
vet3-tgi
Kidney Cancer
KaliVir ImmunotherapeuticsP1C (39)
R130
Kidney Cancer
Shanghai Yunying Medical TechnologyEarly P1C (36)
Sasanlimab
Kidney Cancer
Stephanie BergP2C (34)
13C-Fructose
Kidney Cancer
University of Texas Southwestern Medical CenterN/AD (30)
Acetic-1-13C Acid
Kidney Cancer
University of Texas Southwestern Medical CenterN/AD (30)
Blood, Whole
Kidney Cancer
Institute of Oncology LjubljanaN/AD (30)
Glucose, Anhydrous
Kidney Cancer
University of Texas Southwestern Medical CenterN/AD (30)
Lactate
Kidney Cancer
University of Texas Southwestern Medical CenterN/AD (30)
Neo-811
Kidney Cancer
Neomorph, IncP1NR ()
Showing 51 to 69 of 69 assets
PreviousPage 2 of 2Next